EA201000471A1 - Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин - Google Patents

Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин

Info

Publication number
EA201000471A1
EA201000471A1 EA201000471A EA201000471A EA201000471A1 EA 201000471 A1 EA201000471 A1 EA 201000471A1 EA 201000471 A EA201000471 A EA 201000471A EA 201000471 A EA201000471 A EA 201000471A EA 201000471 A1 EA201000471 A1 EA 201000471A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
tslp
proteins
lymphopoethine
antigenselvating
Prior art date
Application number
EA201000471A
Other languages
English (en)
Other versions
EA022796B1 (ru
Inventor
Майкл Р. Комо
Джеймс Ф. Смозерс
Бо-рин П. Юн
Кристофер Мелин
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40242598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201000471(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA201000471A1 publication Critical patent/EA201000471A1/ru
Publication of EA022796B1 publication Critical patent/EA022796B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее описание (раскрытие) включает композиции и способы, относящиеся к антигенсвязывающим белкам, которые связываются с человеческим тимусным стромальным лимфопоэтином (TSLP), включая антитела. В конкретных вариантах изобретения раскрытие включает полностью человеческие, гуманизированные и химерные антитела против TSLP и производные таких антител. Помимо этого, раскрытие включает нуклеиновые кислоты, кодирующие такие антитела и фрагменты и производные антител, и способы получения и применения таких антител, включая способы лечения и предупреждения связанных с TSLP воспалительных и фиброзных расстройств.
EA201000471A 2007-09-10 2008-09-09 Антитело, способное связывать тимусный стромальный лимфопоэтин, нуклеиновая кислота, его кодирующая, экспрессирующий вектор, клетка-хозяин, гибридома, способ получения антитела и его применение EA022796B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97117807P 2007-09-10 2007-09-10
US9167608P 2008-08-25 2008-08-25
PCT/US2008/010510 WO2009035577A1 (en) 2007-09-10 2008-09-09 Antigen binding proteins capable of binding thymic stromal lymphopoietin

Publications (2)

Publication Number Publication Date
EA201000471A1 true EA201000471A1 (ru) 2010-10-29
EA022796B1 EA022796B1 (ru) 2016-03-31

Family

ID=40242598

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201590631A EA201590631A1 (ru) 2007-09-10 2008-09-09 Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин
EA201000471A EA022796B1 (ru) 2007-09-10 2008-09-09 Антитело, способное связывать тимусный стромальный лимфопоэтин, нуклеиновая кислота, его кодирующая, экспрессирующий вектор, клетка-хозяин, гибридома, способ получения антитела и его применение

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201590631A EA201590631A1 (ru) 2007-09-10 2008-09-09 Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин

Country Status (36)

Country Link
US (5) US7982016B2 (ru)
EP (3) EP2205635B1 (ru)
JP (7) JP5956716B2 (ru)
KR (2) KR20140141666A (ru)
CN (2) CN104231081B (ru)
AR (1) AR068508A1 (ru)
AU (1) AU2008300028B2 (ru)
CA (1) CA2698382C (ru)
CL (2) CL2008002668A1 (ru)
CR (2) CR11319A (ru)
CY (2) CY1117702T1 (ru)
DK (1) DK2205635T3 (ru)
EA (2) EA201590631A1 (ru)
ES (1) ES2581229T3 (ru)
FR (1) FR22C1059I2 (ru)
HK (1) HK1145843A1 (ru)
HR (1) HRP20160638T1 (ru)
HU (2) HUE028361T2 (ru)
IL (3) IL204069A (ru)
JO (1) JO3351B1 (ru)
LT (1) LT2205635T (ru)
MX (1) MX2010002590A (ru)
MY (1) MY150242A (ru)
NL (1) NL301207I2 (ru)
NO (1) NO2022055I1 (ru)
NZ (1) NZ583933A (ru)
PE (2) PE20140232A1 (ru)
PH (1) PH12017501025A1 (ru)
PL (1) PL2205635T3 (ru)
PT (1) PT2205635T (ru)
RS (1) RS54950B1 (ru)
SG (2) SG178781A1 (ru)
SI (1) SI2205635T1 (ru)
TW (2) TWI449709B (ru)
WO (1) WO2009035577A1 (ru)
ZA (1) ZA201001895B (ru)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
BRPI0720271A2 (pt) 2006-12-14 2014-01-28 Schering Corp Anticorpo anti-tslp projetado
EP2803675A3 (en) 2008-01-25 2014-12-24 Amgen, Inc Ferroportin antibodies and methods of use
JP6077856B2 (ja) 2009-11-04 2017-02-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 操作型抗ｔｓｌｐ抗体本出願は、米国特許仮出願第６１／２９７，００８号（２０１０年１月２１日出願）、および米国特許仮出願第６１／２５８，０５１号（２００９年１１月４日出願）の利益を主張し、該仮出願は各々、引用によりその全体が本明細書に組み込まれる。
SG188591A1 (en) * 2010-09-22 2013-04-30 Amgen Inc Carrier immunoglobulins and uses thereof
WO2013067051A1 (en) * 2011-11-03 2013-05-10 Merck Sharp & Dohme Corp. Biomarkers for tslp treatment
WO2013163377A1 (en) * 2012-04-27 2013-10-31 Novo Nordisk A/S Human cd30 ligand antigen binding proteins
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
US11427627B2 (en) 2013-09-05 2022-08-30 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015118124A1 (en) * 2014-02-06 2015-08-13 Vib Vzw Thymic stromal lymphopoietin receptor antagonist
CN106413779B (zh) 2014-05-07 2020-06-05 安姆根有限公司 具有减震元件的自助注射器
CA2949237C (en) 2014-05-16 2022-08-23 Amgen Inc. Assay for detecting th1 and th2 cell populations
SG11201609963PA (en) 2014-06-03 2016-12-29 Amgen Inc Devices and methods for assisting a user of a drug delivery device
MX2021014323A (es) 2014-10-14 2023-02-02 Amgen Inc Dispositivo de inyección de fármaco con indicadores visuales y audibles.
EA038462B1 (ru) 2014-10-23 2021-08-31 Эмджен Инк. Снижение вязкости фармацевтических составов
WO2016100055A1 (en) 2014-12-19 2016-06-23 Amgen Inc. Drug delivery device with live button or user interface field
EP3556411B1 (en) 2015-02-17 2021-06-30 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
WO2016138434A1 (en) 2015-02-27 2016-09-01 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2016142426A1 (en) * 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Tslp binding proteins
CN107849148B (zh) 2015-05-21 2023-09-19 哈普恩治疗公司 三特异性结合蛋白质及使用方法
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
US10000561B2 (en) * 2015-09-09 2018-06-19 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
CR20180154A (es) 2015-09-09 2018-04-12 Novartis Ag Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
EP3386573B1 (en) 2015-12-09 2019-10-02 Amgen Inc. Auto-injector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
US10053515B2 (en) 2016-01-22 2018-08-21 Merck Sharp & Dohme Corp. Anti-coagulation factor XI antibodies
GB201615588D0 (en) * 2016-09-14 2016-10-26 Glaxosmithkline Ip Dev Ltd TSLP Binding Proteins
EP3721922B1 (en) 2016-03-15 2022-05-04 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017174556A1 (en) 2016-04-05 2017-10-12 Vib Vzw Novel tslp inhibitors
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (es) 2016-05-13 2019-02-21 Amgen Inc Montaje de cubierta protectora de vial.
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
MY201852A (en) 2016-06-14 2024-03-20 Merck Sharp & Dohme Llc Anti-coagulation factor xi antibodies
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
JP6925421B2 (ja) * 2016-08-05 2021-08-25 ワイ−バイオロジクス・インコーポレイテッド プログラム化された細胞死蛋白質リガンド−１（ｐｄ−ｌ１）に対する抗体及びその用途
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
US20190358411A1 (en) 2017-01-17 2019-11-28 Amgen Inc. Injection devices and related methods of use and assembly
EP3383916B1 (en) 2017-01-24 2022-02-23 I-Mab Biopharma US Limited Anti-cd73 antibodies and uses thereof
MX2019009625A (es) 2017-02-17 2019-10-09 Amgen Inc Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
JP7280189B2 (ja) 2017-02-17 2023-05-23 アムジエン・インコーポレーテツド 薬物送達装置用の挿入機構
JP2020508803A (ja) 2017-03-06 2020-03-26 アムジエン・インコーポレーテツド 作動防止特徴部を備える薬物送達デバイス
SG11201908058UA (en) 2017-03-07 2019-09-27 Amgen Inc Needle insertion by overpressure
JP2020509837A (ja) 2017-03-09 2020-04-02 アムジエン・インコーポレーテツド 薬剤送達装置のための挿入機構
MA47775A (fr) 2017-03-14 2020-01-22 Amgen Inc Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire
CN110446512B (zh) 2017-03-28 2022-03-18 美国安进公司 柱塞杆和注射器组件系统以及方法
JOP20190243A1 (ar) 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
US12103979B2 (en) 2017-04-28 2024-10-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
WO2018226515A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
EP3641857A1 (en) 2017-06-22 2020-04-29 Amgen Inc. Device activation impact/shock reduction
CA3063921A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
CN109206514B (zh) * 2017-07-03 2019-10-08 拜西欧斯（北京）生物技术有限公司 Tslp单克隆抗体及其制备方法和应用
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
EP4292576A3 (en) 2017-07-21 2024-01-17 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
EP3658203B1 (en) 2017-07-25 2022-08-31 Amgen Inc. Drug delivery device with gear module and related method of assembly
MA49676A (fr) 2017-07-25 2020-06-03 Amgen Inc Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
AU2018312564A1 (en) 2017-08-01 2020-01-30 Amgen Inc. Systems and methods for performing a real-time glycan assay of a sample
CA3071676A1 (en) 2017-08-01 2019-02-07 Amgen Inc. Systems and methods for real time preparation of a polypeptide sample for analysis with mass spectrometry
EP3664863A2 (en) 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
CN110997939A (zh) 2017-08-16 2020-04-10 免疫医疗有限责任公司 用于治疗特应性皮炎的组合物和方法以及治疗选择
MA49897A (fr) 2017-08-18 2020-06-24 Amgen Inc Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
ES2939292T3 (es) 2017-10-04 2023-04-20 Amgen Inc Adaptador de flujo para dispositivo de administración de fármacos
IL272636B2 (en) 2017-10-06 2024-10-01 Amgen Inc Drug delivery device with combination assembly and related assembly method
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
IL287045B1 (en) 2017-10-13 2024-10-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
EP3703778A1 (en) 2017-11-03 2020-09-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
EP3707075A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Fill-finish assemblies and related methods
JP2021501616A (ja) 2017-11-06 2021-01-21 アムジエン・インコーポレーテツド 配置及び流量検出を備える薬物送達デバイス
CN111225696B (zh) 2017-11-10 2023-07-18 安进公司 用于药物递送装置的柱塞
MX2020004996A (es) 2017-11-16 2020-08-27 Amgen Inc Un mecanismo de pestillo de puerta para un dispositivo de administracion de farmacos.
EP4321870A3 (en) 2018-03-13 2024-04-03 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
JP7411560B2 (ja) 2018-03-13 2024-01-11 アムジエン・インコーポレーテツド 質量分光測定法による分析のためのポリペプチドの連続消化
AU2019243848A1 (en) 2018-03-26 2020-09-17 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
MX2021000748A (es) 2018-07-24 2021-03-26 Amgen Inc Dispositivos de suministro para administrar farmacos.
EP3826699A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Delivery devices for administering drugs
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
US12109389B2 (en) 2018-07-31 2024-10-08 Amgen Inc. Fluid path assembly for a drug delivery device
EP3856284A1 (en) 2018-09-24 2021-08-04 Amgen Inc. Interventional dosing systems and methods
MX2021003554A (es) 2018-09-25 2021-05-27 Harpoon Therapeutics Inc Proteinas de union a dll3 y metodos de uso.
CA3110371A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
CN112805048B (zh) 2018-10-02 2023-09-22 安进公司 具有内部力传递的用于药物递送的注射系统
JP7547325B2 (ja) 2018-10-05 2024-09-09 アムジエン・インコーポレーテツド 投薬量インジケータを有する薬物送達デバイス
EP3866890A1 (en) 2018-10-15 2021-08-25 Amgen Inc. Drug delivery device having damping mechanism
JP2022504805A (ja) 2018-10-15 2022-01-13 アムジエン・インコーポレーテツド 薬物送達デバイスのプラットフォーム式組み立てプロセス
EP3873566A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
US12000775B2 (en) 2018-12-14 2024-06-04 Amgen Inc. System suitability method for use with protein concentration determination by slope
US11452738B2 (en) 2019-01-04 2022-09-27 Empirico Inc. Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
US20220137061A1 (en) 2019-02-14 2022-05-05 Amgen Inc. Systems And Methods For Preparing A Sample and Performing A Real-Time Assay Of The Sample
WO2020172293A1 (en) 2019-02-20 2020-08-27 Amgen Inc. Methods of determining protein stability
US20230035363A1 (en) 2019-03-04 2023-02-02 Amgen Inc. In vivo reversibility of high molecular weight species
CA3133459A1 (en) 2019-03-27 2020-10-01 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
CA3137360A1 (en) 2019-04-24 2020-10-29 Amgen Inc. Syringe sterilization verification assemblies and methods
AU2020286889A1 (en) 2019-06-04 2022-01-20 Jiangsu Hengrui Medicine Co., Ltd. Antibody capable of binding to thymic stromal lymphopoietin and use thereof
US20220260584A1 (en) 2019-06-05 2022-08-18 Amgen Inc. Methods of identifying attributes of therapeutic proteins
EP4017560A2 (en) 2019-08-23 2022-06-29 Amgen, Inc Drug delivery device with configurable needle shield engagement components and related methods
JP2022549329A (ja) 2019-09-26 2022-11-24 アムジェン インコーポレイテッド 抗体組成物を製造する方法
BR112022008031A2 (pt) * 2019-10-28 2022-07-12 Medimmune Ltd Formulações de pó seco de anticorpos de ligação à linfopoietina estromal tímica (tslp) e métodos de uso das mesmas
CN112876564B (zh) 2019-11-29 2022-07-15 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
MX2022004919A (es) * 2019-12-13 2022-05-16 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Anticuerpo anti-linfopoyetina estromal timica (tslp) y sus usos.
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN111171150B (zh) * 2020-02-05 2020-12-08 北京智仁美博生物科技有限公司 抗人tslp抗体及其用途
BR112022016010A2 (pt) 2020-02-13 2022-12-20 Amgen Inc Formulações de anticorpos anti-tslp humanos e métodos de tratamento de doenças inflamatórias
EP4103605A1 (en) 2020-02-13 2022-12-21 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
UY39089A (es) 2020-02-18 2021-08-31 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos
CN111662379B (zh) * 2020-05-09 2021-03-02 江苏省疾病预防控制中心(江苏省公共卫生研究院) 抗新型冠状病毒的抗体、制备方法和应用
JP2023526469A (ja) * 2020-05-20 2023-06-21 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク ＳＡＲＳ－ＣｏＶ－２に対する強力な中和抗体、その生成および使用
EP4162257A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
EP4214226A1 (en) 2020-09-18 2023-07-26 Amgen Inc. Methods of processing a sample for peptide mapping analysis
JP2023548767A (ja) 2020-10-15 2023-11-21 アムジエン・インコーポレーテツド 抗体製造方法における相対不対グリカン
US20240010672A1 (en) 2020-11-05 2024-01-11 Amgen Inc. Materials and methods for protein processing
CN114437212B (zh) * 2020-11-06 2023-03-14 上海麦济生物技术有限公司 抗人胸腺基质淋巴细胞生成素抗体及其制备方法和应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113501878B (zh) 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
JP2024504441A (ja) * 2021-02-04 2024-01-31 スタイドソン・（ベイジン）・バイオファーマシューティカルズ・カンパニー・リミテッド 胸腺間質性リンパ球新生因子を特異的に認識する抗体およびその使用
KR20240000537A (ko) 2021-04-23 2024-01-02 암젠 인크 항-tslp 항체 조성물 및 이의 용도
KR20230175245A (ko) 2021-04-23 2023-12-29 암젠 인크 변형된 항-tslp 항체
EP4341161A1 (en) 2021-05-21 2024-03-27 Amgen Inc. Method of optimizing a filling recipe for a drug container
JP2024520873A (ja) * 2021-05-30 2024-05-24 バイオロジック デザイン リミテッド 操作された二重結合抗体およびその使用
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CN113069543B (zh) * 2021-06-07 2021-08-06 迈威(上海)生物科技股份有限公司 包含抗胸腺基质淋巴细胞生成素的单克隆抗体的液体组合物
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023070948A1 (zh) * 2021-11-01 2023-05-04 江苏荃信生物医药股份有限公司 包含抗人胸腺基质淋巴细胞生成素(tslp)单克隆抗体的浓缩溶液的制备方法及液体制剂
CA3237662A1 (en) 2021-11-09 2023-05-19 Amgen Inc. Production of therapeutic proteins
CN117209603B (zh) * 2021-12-02 2024-02-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN114369654B (zh) * 2021-12-21 2023-11-07 广州市妇女儿童医疗中心 川崎病的生物标志物及其应用
EP4453030A1 (en) * 2021-12-24 2024-10-30 Inmagene Pte. Ltd. Novel anti-tslp antibodies
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
US12110324B2 (en) * 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
TW202426485A (zh) 2022-10-26 2024-07-01 美商安進公司 抗ｔｓｌｐ抗體組成物及其用途
WO2024163978A2 (en) 2023-02-02 2024-08-08 Medimmune, Llc Treatment of chronic rhinosinusitis with anti-tslp antibody
WO2024174895A1 (zh) * 2023-02-23 2024-08-29 四川科伦博泰生物医药股份有限公司 一种靶向tslp的单克隆抗体制剂
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JPS58117537A (ja) 1982-01-06 1983-07-13 Toray Ind Inc 感光性樹脂組成物
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990015870A1 (en) 1989-06-15 1990-12-27 Immunex Corporation Interleukin-7 receptors
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
DE69327582T2 (de) 1992-04-30 2000-08-03 Amgen Inc., Thousand Oaks Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
WO1995000103A2 (en) 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
AU729035B2 (en) 1997-06-12 2001-01-25 Novartis Ag Artificial antibody polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
CA2323776C (en) 1998-03-19 2010-04-27 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6844170B1 (en) * 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US20030099947A1 (en) 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
EP1897949B1 (en) 1998-09-21 2014-11-12 Merck Sharp & Dohme Corp. Human interleukin-B50. Therapeutic uses
DK1129190T4 (en) 1998-11-13 2017-04-03 Immunex Corp Human TSLP DNA and polypeptides
AU2396600A (en) 1998-12-30 2000-07-31 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
EP1282435A2 (en) 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
AU2001271624A1 (en) 2000-06-28 2002-01-08 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
CA2413673C (en) 2000-06-28 2018-01-09 Amgen Inc. Thymic stromal lymphopoietin receptor molecules and uses thereof
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CN1234728C (zh) * 2001-05-16 2006-01-04 上海睿星基因技术有限公司 新的人淋巴因子、其编码序列及用途
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
MXPA04000631A (es) 2001-07-23 2004-06-25 Immunex Corp Linfopoyetina timica estromatica humana modificada.
EP2311869B2 (en) 2002-02-01 2020-06-17 Merck Sharp & Dohme Corp. Use of mammalian cytokine-related reagents
HRP20020453A2 (en) 2002-05-23 2003-12-31 Pliva D D 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
CN101124240B (zh) 2003-07-18 2013-12-18 安姆根有限公司 肝细胞生长因子的特异性结合物
PL1651247T3 (pl) 2003-07-18 2009-04-30 Schering Corp Leczeni i diagnozowanie nowotworów przy użyciu limfopoetyny zrębu grasicy
CN1922210A (zh) 2003-12-19 2007-02-28 健泰科生物技术公司 可用作治疗剂的单价抗体片段
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
WO2006023791A2 (en) 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
CA2587903A1 (en) * 2004-11-17 2006-05-26 Amgen Fremont Inc. Fully human monoclonal antibodies to il-13
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
AU2007230868B2 (en) 2006-01-13 2012-02-02 Irm Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
BRPI0720271A2 (pt) 2006-12-14 2014-01-28 Schering Corp Anticorpo anti-tslp projetado
EA201000006A1 (ru) 2007-06-20 2010-10-29 Айрм Ллк Способы и композиции для лечения аллергических заболеваний
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
IL204069A (en) 2017-03-30
AU2008300028B2 (en) 2014-12-18
EA022796B1 (ru) 2016-03-31
PE20140232A1 (es) 2014-02-28
PL2205635T3 (pl) 2016-12-30
HUS2200051I1 (hu) 2022-12-28
JP2023065375A (ja) 2023-05-12
EP2703414A1 (en) 2014-03-05
MX2010002590A (es) 2010-03-26
CY2022036I1 (el) 2023-01-05
PH12017501025A1 (en) 2018-01-29
NL301207I2 (nl) 2023-02-02
AR068508A1 (es) 2009-11-18
TWI449709B (zh) 2014-08-21
US20110274687A1 (en) 2011-11-10
ES2581229T3 (es) 2016-09-02
JP2020058365A (ja) 2020-04-16
JP5956716B2 (ja) 2016-07-27
CY1117702T1 (el) 2017-05-17
PT2205635T (pt) 2016-07-13
US20160152700A1 (en) 2016-06-02
NO2022055I1 (no) 2022-12-09
CN101809035A (zh) 2010-08-18
CA2698382C (en) 2015-07-14
CR20150095A (es) 2015-04-06
MY150242A (en) 2013-12-31
HRP20160638T1 (hr) 2016-07-01
JP2021191758A (ja) 2021-12-16
US10287348B2 (en) 2019-05-14
SG178781A1 (en) 2012-03-29
KR101597371B1 (ko) 2016-02-26
CR11319A (es) 2010-04-21
SG10201506251YA (en) 2015-11-27
CL2008002668A1 (es) 2009-08-14
DK2205635T3 (en) 2016-07-18
TW200918554A (en) 2009-05-01
US8163284B2 (en) 2012-04-24
US7982016B2 (en) 2011-07-19
CL2012003245A1 (es) 2013-03-22
FR22C1059I1 (fr) 2023-02-03
JO3351B1 (ar) 2019-03-13
SI2205635T1 (sl) 2016-09-30
US20200071393A1 (en) 2020-03-05
RS54950B1 (sr) 2016-11-30
LT2205635T (lt) 2016-09-26
EP2205635B1 (en) 2016-05-25
US20090238823A1 (en) 2009-09-24
CN104231081A (zh) 2014-12-24
JP2010538608A (ja) 2010-12-16
HK1145843A1 (zh) 2011-05-06
PE20110668A1 (es) 2011-10-01
AU2008300028A1 (en) 2009-03-19
JP2019038843A (ja) 2019-03-14
CA2698382A1 (en) 2009-03-19
EP2205635A1 (en) 2010-07-14
ZA201001895B (en) 2011-02-23
IL250900A0 (en) 2017-04-30
HUE028361T2 (en) 2016-12-28
CY2022036I2 (el) 2023-03-24
FR22C1059I2 (fr) 2023-12-22
EP3524622A1 (en) 2019-08-14
JP2015091820A (ja) 2015-05-14
CN104231081B (zh) 2022-01-11
KR20100067660A (ko) 2010-06-21
NL301207I1 (nl) 2022-12-21
US20120190829A1 (en) 2012-07-26
CN101809035B (zh) 2014-07-09
IL265854A (en) 2019-06-30
KR20140141666A (ko) 2014-12-10
EA201590631A1 (ru) 2016-03-31
TW201412774A (zh) 2014-04-01
WO2009035577A1 (en) 2009-03-19
NZ583933A (en) 2012-07-27
JP2017110011A (ja) 2017-06-22
US9284372B2 (en) 2016-03-15

Similar Documents

Publication Publication Date Title
EA201000471A1 (ru) Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин
PH12014502527A1 (en) St2 antigen binding proteins
AU2009260320A8 (en) Antibodies to IL-6 and their uses
NO20091534L (no) Preparator og fremgangsmater som vedrorer glukagonreseptorantistoff
EA201390278A1 (ru) Антитела к ох40 и способы их применения
MA34004B1 (fr) Protéines de liaison à cd127
WO2014114651A9 (en) Tnf-alpha antigen-binding proteins
MX2010002269A (es) Composiciones y metodos que comprenden proteinas de union para adalimumab.
PH12012501006A1 (en) Compositions and methods relating to anti-igf-1 receptor antibodies
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
WO2013011076A3 (en) Tnf -alpha antigen- binding proteins with increased fcrn binding
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
IN2009CN03372A (ru)
EA201890928A1 (ru) Антигенсвязывающие белки, которые активируют лептиновый рецептор
WO2013192596A3 (en) Antigen binding proteins that bind ccr2
EA201000053A1 (ru) Новые антитела
NZ578068A (en) Allergen-binding ige monoclonal antibodies and method for preparing hypoallergens
EA201790437A1 (ru) Антигенсвязывающие белки, связывающиеся с cxcr3
WO2013191982A3 (en) Antigen binding proteins that bind igf1r
EA200900991A1 (ru) Новые антитела против igf-1r
AR110159A2 (es) Anticuerpo humano anti-tslp (linfopoyetina estromal tímica), y su empleo en el tratamiento de una afección inflamatoria relacionada con la tslp

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM